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Analysis of ADCs by native electrospray MS 
Summary/Abstract 
Mass spectrometry performed in non-denaturing conditions (native MS) has proven its utility 
for the quantitative and qualitative analysis of antibody-drug conjugates (ADCs), especially 
when ADCs’ subunits involve non-covalent interactions (i.e. cysteine-conjugated ADCs).  Its 
hyphenation to ion mobility spectroscopy (IM-MS) allows differentiation of gas-phase ions 
based on their rotationally averaged collision cross section providing an additional dimension 
of conformational characterization of ADCs. More recently, size exclusion chromatography 
(SEC) appeared as an interesting technique to perform online buffer exchange in an automated 
way prior to native MS/IM-MS analysis. Online SEC-native MS/IM-MS allows the global 
structural characterization of ADCs and the assessment of some critical quality attributes 
(CQAs) required for ADC release on the market, such as drug load distribution (DLD), drug-
to-antibody ratio (DAR), the average DAR (DARav), and the relative amount of unconjugated 
mAb. 
 
 Keywords  
Native mass spectrometry, Antibody drug conjugate, Ion mobility mass spectrometry, Size 
exclusion chromatography-native mass spectrometry 
  
1. Introduction 
ADCs are tripartite molecules designed to improve the therapeutic efficacy of monoclonal 
antibodies (mAbs) through the covalent addition of a cytotoxic molecule via a linker[1]. The 
heterogeneity associated to ADCs can vary, depending on the bioconjugation chemistry used 
to attach the cytotoxic molecules to the mAb structure[2]. Several studies have shown the 
suitability of native mass spectrometry (MS) for ADC analysis[3-13]. The reduced charge state 
of the ions under non-denaturing conditions facilitates the identification and quantification of 
all the different DAR populations that can be potentially formed during the conjugation process. 
Furthermore, the rotationally averaged collision cross section (CCS) of each individual DAR 
population can be determined by using ion mobility coupled to mass spectrometry (IM-MS) to 
assess the impact of the conjugation process on the overall conformation of the original mAb[6; 
7]. However, sample preparation (desalting) is still mostly manual, labor intensive and time-
consuming prior to native IM-MS analysis. SEC-native MS not only allows on-line buffer 
exchange within few minutes but also provides separation, identification and quantification of 
high/low molecular weight species[9]. Online SEC-native MS can be easily implemented in 
high throughput automated environments thus pushing native MS approaches to the forefront 
of ADC characterization in R&D laboratories.  
 
2. Materials 
All solutions are prepared with ultrapure water.  
2.1. Mobile phase for SEC-native MS 
100 mM AcONH4, pH 6.8: weigh 3.08 g of AcONH4 in a 500 mL volumetric flask. Add 
400 mL of milli-Q water with stirring. No pH adjustment is needed. 
2.2. Deglycosylated ADCs 
ADCs were obtained as European Union pharmaceutical-grade drug product from their 
respective manufacturers. The deglycosylation was performed by incubating for 30 min at 
37°C one unit of IgGZERO (Genovis) per microgram of ADC. 
2.3. Manual buffer exchange 
1. 150 mM AcONH4, pH 6.8: weigh 578 mg of AcONH4 in a 50 mL falcon. Add 50 mL 
of milli-Q water with stirring. 
2.4. Cesium Iodide solution for Mass Spectrometer calibration 
Prepare a 2 g/L solution of cesium iodide in 50/50 isopropanol/water (v/v). 
a. Synapt G2 
1. The automated chip-based nanoelectrospray device (Triversa Nanomate, Advion, 
Ithaca, USA) is operated in the positive ion mode. Set the capillary voltage and the 
nitrogen nanoflow at 1.75 kV and 0.60 psi respectively. 
2. In MassLynx MS Tune windows, set the following parameters: 
Operate the instrument in positive and sensitivity modes with a m/z range from 1 000 
to 10 000.  
Nanoflow+ panel: Sampling Cone: 120 V. Extraction con: 5 V. Source Temperature: 
90 °C. The Capillary Voltage and the gas flows are not used in the Nanomate interface 
setup. 
Instrument: Trap and Transfer Collision Energy are turned off. 
3. Start a 2 min TOF-MS acquisition with a m/z range from 1 000 to 10 000. 
4. Average the signal over the 2 min in the Chromatogram panel. In the spectrum panel, 
a Spectrum Smooth with ± 10 Smooth window and a number of smooths of 2 with a 
“Mean” Smoothing method were realized. On the smooth spectrum, the TOF Spectrum 
Center with a min peak width at half height of 2 and a Centroid top at 80.00 % was 
selected. 
5. In the Acquity UPLC Console, select “Create Calbration”. 
6. In the calibration profile editor, select the right Mass Calibration Profile (CsI in the 
1 000 – 10 000 m/z range in positive and sensitivity modes). 
7. The Reference Compound (Csi_1000-10000 positive) with reference masses from 
1 172.1450 to 7 927.2031 Da) is used for the calibration. 
b. Exactive Plus EMR 
1. Using HESI source and the 500 µL Hamilton™ syringe, deliver cesium iodide solution 
with a flow rate set to 10 µL/min. 
2. In the MS Tune page manually set the following parameters: Operate the instrument in 
positive mode with a m/z range from 1,000 to 20,000.  Apply 25 eV and 100 eV for the 
CID and CE parameters, respectively. The source temperature is set at 250°C, the 
capillary voltage is set to 4 kV and the gas flows is set to 10 u.a. The trapping gas 
pressure is set to 7 u.a. The ion optics are set to 4 V for injection, inter and bent 
flatapoles.  Set the nominal resolution at 17,500 and activate the EMR mode.  
3. To perform the calibration, wait for a stable TIC (<12 %) then select “Calibrate” and 
check “EMR MS Mass Calibration (pos)”.  
2.5. Ion mobility calibrants 
1. 10 mM AcONH4: weight 38 µg of AcONH4 in 50 mL falcon. Add 50 mL of mili-Q 
water with stirring.  
2. Weigh between 400 µg and 900 µg of concanavalin A from canavalia ensiformis, 
alcohol dehydrogenase from saccharomyces cerevisiae, and pyruvate kinase from rabbit 
muscle. Dissolve each individual calibrant in 100 µL of 10 mM ammonium acetate to 
reach a final tetrameric concentration between 30-40 µM (Note 1).  
3. Perform manual buffer exchange using a 50 kD microconcentrator (see 2.3. section). 
4. Use the nanodrop spectrophotometer to determine the concentration of the calibrant 
solutions after manual desalting. 
5. Add the required volume of 10 mM AcONH4 solution to get a final concentration of 10 
µM for each individual calibrant solution.  
 
3. Methods  
3.1 ADC sample preparation 
1. A microconcentrator with an appropriate MWCO (such as Vivaspin 50-kD cutoff for 
classical ADCs, Sartorius, Göttingen, Germany) is used for manual buffer exchange. 
2. Equilibrate the microconcentrator by adding 500 µL of 150 mM AcONH4 at 14 000 g 
over 2 min and remove the eluate. 
3. Repeat step 3 twice. 
4. Load between 25-50 µL of sample. Add AcONH4 buffer to get a final volume of 500 
µL. 
5. Centrifuge for 10 min at 14 000 g to concentrate down to 50 µL and remove the eluate. 
Add 450 µL of AcONH4 buffer. Repeat the dilution concentration cycle five times. 
6. After the last cycle, transfer the 50 µL of sample to an Eppendorf tube. Protein 
concentration is determined by UV absorbance using a NanoDrop spectrophotometer 
(Thermo Fisher Scientific, France). 
 
3.2 Mass spectrometer calibration 
a. Synapt G2 
1. The automated chip-based nanoelectrospray device (Triversa Nanomate, Advion, 
Ithaca, USA) is operated in the positive ion mode. Set the capillary voltage and the 
nitrogen nanoflow at 1.75 kV and 0.60 psi respectively. 
2. In MassLynx MS Tune windows, set the following parameters: 
Operate the instrument in positive and sensitivity modes with a m/z range from 1 000 
to 10 000.  
Nanoflow+ panel: Sampling Cone: 120 V. Extraction con: 5 V. Source Temperature: 
90 °C. The Capillary Voltage and the gas flows are not used in the Nanomate interface 
setup. 
Instrument: Trap and Transfer Collision Energy are turned off. 
3. Start a 2 min TOF-MS acquisition with a m/z range from 1 000 to 10 000. 
4. Average the signal over the 2 min in the Chromatogram panel. In the spectrum panel, 
a Spectrum Smooth with ± 10 Smooth window and a number of smooths of 2 with a 
“Mean” Smoothing method were realized. On the smooth spectrum, the TOF Spectrum 
Center with a min peak width at half height of 2 and a Centroid top at 80.00 % was 
selected. 
5. In the Acquity UPLC Console, select “Create Calbration”. 
6. In the calibration profile editor, select the right Mass Calibration Profile (CsI in the 
1 000 – 10 000 m/z range in positive and sensitivity modes). 
7. The Reference Compound (Csi_1000-10000 positive) with reference masses from 
1 172.1450 to 7 927.2031 Da) is used for the calibration. 
b. Exactive Plus EMR 
1. Using HESI source and the 500 µL Hamilton™ syringe, deliver cesium iodide solution 
with a flow rate set to 10 µL/min. 
2. In the MS Tune page manually set the following parameters: Operate the instrument in 
positive mode with a m/z range from 1,000 to 20,000.  Apply 25 eV and 100 eV for the 
CID and CE parameters, respectively. The source temperature is set at 250°C, the 
capillary voltage is set to 4 kV and the gas flows is set to 10 u.a. The trapping gas 
pressure is set to 7 u.a. The ion optics are set to 4 V for injection, inter and bent 
flatapoles.  Set the nominal resolution at 17,500 and activate the EMR mode.  
3. To perform the calibration, wait for a stable TIC (<12 %) then select “Calibrate” and 
check “EMR MS Mass Calibration (pos)”.  
 
3.3 Direct infusion on Exactive Plus EMR for native MS experiment 
a. Mass spectrometry setting for native MS experiment 
1. Desalt between 100 µg and 150 µg of ADC in 150 mM ammonium acetate. 
2. Determine the concentration of the ADC solution after desalting by UV absorbance 
using NanoDrop spectrophotometer (Thermo Fisher Scientific, France). 
3. Prior to ADC mass analysis, perform Exactive Plus EMR calibration with 8 µL of 
cesium iodide solution (see 2.4). 
4. Connect the automated chip-based nanoESI infusion source (Triversa Nanomate, 
Advion, Ithaca, USA) to the Exactive Plus EMR. 
5. In the Tune page, set the following parameters: Positive mode with a m/z range from 1 
000 to 14 000. Activate the EMR mode and set the trapping gas pressure at 7 u.a., the 
ion optics at 8 V, 7 V, 6V for inter, injection and bent flatapoles respectively, the S-lens 
RF voltage at 200 V, the temperature at 250°C, the fragmentation parameters at 75 eV 
and 10 eV for CID and CE values, respectively. Select a nominal resolution of 17 500.  
6. Start a 2 min acquisition with a stable TIC. The mass spectrum is presented in Figure 
1a. 
b. Data interpretation 
1. In BioPharma Finder 2.0, select your raw data file and Intact Protein Analysis. 
2. In chromatogram & Source Spectra, select a m/z range from 5 500 to 7 500. In ReSpect 
Deconvolution Algorithm, set a Model Mass Range from 145 000 to 160 000 with a 
mass tolerance of 10 ppm. Select a charge state range from 18 to 35. For the Choice of 
Peak Model, select Raw File Specific for the Resolution at 400 m/z. 
3. Process the algorithm in order to have the deconvoluted spectrum presented in Figure 
1b. 
4. For average DAR (DARav), see 3.4. [Figure 1 near here] 
3.4 Direct infusion on Synapt G2 for native MS/IM-MS experiment 
a. Mass spectrometry settings for native MS experiment 
1. Desalt between 100 µg and 150 µg of ADC in 150 mM ammonium acetate. 
2. Determine the concentration of the ADC solution after desalting by UV absorbance 
using NanoDrop spectrophotometer (Thermo Fisher Scientific, France). 
3. Connect the automated chip-based nanoESI infusion source (Triversa Nanomate, 
Advion, Ithaca, USA) to the Synapt G2 HDMS (Waters, Manchester, UK). 
4. The analysis on the Synapt G2 HDMS is performed in sensitive mode.  
5. Prior to ADC mass analysis, perform Synapt G2 calibration with 8 µL of cesium iodide 
solution (see 2.4). 
6. In the MassLynx Tune windows set the following parameters: Positive ion mode, m/z 
range from 1000 to 10000, sampling cone: 180 V (Note 2), backing pressure: 6 mbar, 
source offset: 5 V, source temperature: 90°C, trap collision energy: 10 V, transfer 
collision energy: 5 V, trap gas: 5 mL/min, scan time: 4 s, and acquisition time: 2 min.  
7. Deliver among 10-20 µL of ADC solution at 5 µM concentration. 
8. In MaxEnt 1, the ranges are set from 145000 to 162000 with a resolution of 1 
Da/channel. The width at half height is set to 2 Da for the uniform Gaussian. The 
deconvoluted spectrum is presented in Figure 2b. 
9. For the DARav calculation, see 3.4.[Figure 2 near here] 
b. Data interpretation Synapt G2 
1. Open the chromatogram option in MassLynx menu. 
2. Combine the mass signal over the two minutes acquisition time. 
3. Smooth the signal using the following parameters: Smooth window: 10, number of 
smooths: 2, and smoothing method: Mean (Figure 2a). 
4. Perform MaxEnt 1 deconvolution with the following parameters: Ranges 145000-
165000, Resolution: 1.00 Da/channel, Uniform Gaussian width at half height: 5 Da, and 
minimum intensity ratios: 33% left and 33% right (Note 3). 
5. Take the intensities of each individual DAR population to assess the DLD (Figure 2b) 
and calculate the DARav (see section 3.4). 
c. Ion mobility mass spectrometry settings for native IM-MS 
1. For IM-MS, in the MassLynx Tune windows set the following parameters: Positive ion 
mode, m/z range from 1000 to 10000, sampling cone: 80 V (Note 4), backing pressure: 
6 mbar, source offset: 5 V, source temperature: 90°C, trap collision energy: 4 V, transfer 
collision energy: 5 V, trap gas: 5 mL/min, scan time: 4 s, and acquisition time: 2 min.   
2. In the Ion mobility cell set the following parameters: N2 flow rate: 45 mL/min, He flow 
rate: 120 mL/min, IM wave height: 40 V, and IM wave velocity 923 m/s (Note 5). 
3. In the masslynx tune page, activate the Mobility TOF mode in the acquisition mode 
menu. 
4. Deliver among 10-20 µL of ADC solution at 10 µM concentration (Note 6). 
5. Record the mass spectrum. Do not forget to activate the option “add drift time function” 
to record the arrival time distribution of each ion (Note 7).  
6. Deliver among 10-20 µL of each individual solution of IM calibrants previously 
prepared.  
7. Record the IM chromatogram of each individual calibrant in triplicate and under 
identical instrumental conditions as those used for the ADC IM-MS analysis. [Figure 3 
near here]  
d. Data interpretation Ion Mobility Synapt G2 
1. In the chromatogram menu of MassLynx, open the IM function.  
2. Combine the whole mobilogram signal to extract the mass spectrum (Figure 3a). 
3. In your mass spectrum, combine the peak of interest at the half-maximum. The 
chromatogram menu will automatically open, showing the arrival time distribution 
associated with the ion selected previously (Figure 3b).  
4. Take the drift time associated with the center of the ATD Gaussian. 
   
e. Calibration curve to convert drift time on collision cross section (CCS) 
1. Proceed as described in section 3.2.d. to obtain the drift time associated with each peak 
of the calibrant solutions: For concanavalin A take the drift time of the 19+, 20+, and 
21+ charge states, for ADH take the 24+, 25+, and 26+ charge states, and finally for PK 
take the 32+, 33+, and 34+ charge states. 
2. Correct the drift times of all these charge states using the following equation (Note 8): 
 !′ =  ! − ($ ∗ &') )/+,,, 
3. Calculate the reduced cross section (Ω’) of the reference charge states of the calibrant 
systems reported in the literature with the following equation: 
  Ω0 = (Ω12 345 643 7µ)/) 
4. Make a graph ln (td’) vs ln (Ω’), fit the data with a linear equation  
                                                    19 (Ω’) =  5 +  ; 19 ( !′) 
5. Make the final correction of the drift times from the equation:   
                                                        !00 =  !0<()|√µ) 
6. Build a second graph  ?@00AB ΩCDEFGHEIEGF and fit the data with a linear regression         
                                                   Ω12 345 643 = ;  !′′  
7. Use the b and X parameters to convert the drift time of the different DAR populations 
of your ADC sample on CCS values (Figure 3c)with the following equation: 
JJK (9'L) = ( ! − (+. NO &') )/+,,,)<) (+/7µ) ; 
 
3.5 Online SEC-native MS 
a. LC setup for SEC-native MS 
2. The column used is a BEH SEC column 200 Å, 1.7 µm, 4.6 x 150 mm (Note 9). the 
chromatographic system is an Acquity UPLC H-Class system (Waters, Manchester, 
UK) comprising a quaternary solvent manager, a sample manager set at 10°C, a column 
oven at room temperature and a TUV detector operating at 280 and 214 nm. 
3. For the analyses of ADC, the elution is performed in isocratic mode with the following 
flow rate gradient: 0.25 mL/min over 4 min, then 0.1 mL/min over 5.5 min and finally 
0.25 mL/min over 2.5 min. (Note 10), (Note 11). 
4. Load the LC method and equilibrate the LC system with ten column volumes of mobile 
phase (see 2.1). 
b. Native mass spectrometry settings for SEC-native MS experiment 
1. Prior to ADC mass analysis, perform Synapt G2 calibration with 8 µL of cesium iodide 
solution (see 2.4). 
2. For the tune page parameters, the Synapt G2 HDMS is operated in sensitive mode with 
a capillary voltage of 3.0 kV. The sample cone and pressure in the interface region were 
set to 180 V for lysine conjugate and 120 V for cysteine conjugate (Note 2) and 6 mbar, 
respectively. Source and desolvatation temperature were set to 100 and 450°C, 
respectively. Desolvatation and cone gas flows were set at 750 and 60 L/hr, respectively. 
3. The MS file is setup with the following parameters: Start time: 0 min; End time: 12 min; 
Polarity: Positive; Analyser Mode: Sensitivity; Dynamic Range: Normal; Sensitivity: 
Normal; Low Mass: 1 000 Da; High Mass: 10 000 Da; Scan Time: 1.5 sec (Continuum); 
No Trap or Transfer CE. Events for flow state are created to direct salts to waste: 0 min 
Flow State directed to Waste, 4 min Flow State directed to LC, 9 min Flow State directed 
to Waste.  
4. In MassLynx, create a sample list with the MS file, Inlet file, MS tune file. Specify the 
sample position (Bottle). The injected volume should be comprised between 1 and 10 
µL. No manual desalting is needed prior SEC-native MS experiment due to online 
desalting provided by SEC. 
c. Data Interpretation 
1. Chromatogram (Figure 4a) and TIC are obtained in the Chromatogram panel.  
2. In MaxEnt 1, the ranges are set from 145000 to 162000 with a resolution of 1 
Da/channel. The width at half height is set to 2 Da for the uniform Gaussian. The 
deconvoluted spectrum is presented in Figure 4b (Note 12). 
3. For the DARav calculation, see 3.4. [Figure 4 near here] 
d. Ion mobility settings for SEC-native IM-MS experiment 
1. In the MassLynx Tune window set the following parameters: Positive ion mode, m/z 
range from 1 000 to 10 000, sampling cone: 80 V, backing pressure: 6 mbar, source 
offset: 5 V, source temperature: 100°C, Desolvatation temperature: 450°C trap collision 
energy: 4 V, transfer collision energy: 5 V, trap gas: 5 mL/min. 
2. In the Ion mobility cell set the following parameters: N2 flow rate: 45 mL/min, He flow 
rate: 130 mL/min, IM wave height: 40 V, and IM wave velocity 923 m/s. 
3. The MS file is setup with the following parameters: Start time: 0min; End time: 12 min; 
Polarity: Positive; Analyser Mode: Sensitivity; Dynamic Range: Normal; Sensitivity: 
Normal; Low Mass: 1 000 Da; High Mass: 10 000 Da; Scan Time: 1.5 sec (Continuum); 
No Trap or Transfer CE. Check Add Drift Time Function and Maintain Mobility 
Separation. Events for flow state are created to direct salts to waste: 0 min Flow State 
directed to Waste, 4 min Flow State directed to LC, 9 min Flow State directed to Waste.  
4. In MassLynx, create a sample list with the MS file, Inlet file, MS tune file. Specify the 
sample position (Bottle). The injected volume has to be comprised between 1 and 10 
µL. Record each IM experiment in triplicate to calculate a more reliable collisional cross 
section. 
5. Deliver among 1-10 µL of each individual solution of IM calibrants (see 2.5.2). 
6. Record the IM chromatogram of each individual calibrant in triplicate and under 
identical instrumental conditions as those used for the ADC SEC-native MS analysis.  
7. For data interpretation, see 3.2.e 
 
3.6 Average DAR calculation and Drug Load Distribution 
The average DAR value represents the sum of relative peak intensities in the mass spectrum for 
each DAR multiplied by its corresponding number of drugs. It was calculated from the relative 
peak intensities measured from the raw mass spectra, by using the following equation 
PQRHS =  ∑ U ∙  WX
YZ
∑ WXYZ  
Where k is the number of drugs and Ik is the relative peak intensity of DARk. 
 
4. Notes 
1. Ion mobility calibrants have to be chosen depending on the mass and the charge state of 
the analyzed mAb/ADC. Here we chose to use ion mobility calibrants that range from 100 
kDa to 230 kDa and exhibit positive charge states from 15+ to 35+. Usually ADCs are 
proteins around 150 kDa with 20+ to 28+ positive charges under our experimental 
conditions.  
2. The sampling cone (Vc) voltage is a crucial parameter on Waters instrument. A high 
voltage (180 V) increases transmission of high m/z ions along with more efficient 
desolvation[14]. However, high Vc values also favor dissociation of noncovalent 
assemblies, especially for cysteine linked ADCs. An intermediate Vc value of 100-120 V 
is thus usually more adapted. An optimum value has to be found to provide compromise 
between good quality MS signal and maintaining ADC integrity.   
3. The parameters of the MaxEnt1 deconvolution are protein dependent. In particular, the 
mass range and the FWHM have to be optimized for each mAb/ADC. The latter has to be 
chosen as a function of the resolution of the experimental mass spectrum. 
4. The sampling cone voltage applied in the source of the mass spectrometer is an important 
parameter for native IM-MS experiments. Ion heating can occur as a consequence of the 
effect of this acceleration voltage and eventually can lead to conformational changes 
(protein unfolding) on protein structures while ions are transmitted into the mass 
spectrometer. Be sure that the sampling cone voltage you are using allows the transmission 
of your molecular ions of interest and does not induce any structural changes. From our 
experience, 80 V provides a good MS signal (intensity and resolution) without modifying 
ADCs conformation. 
5. These parameters are going to drive the separation of the ions in the ion mobility cell. 
They have to be carefully optimized to ensure ion focusing (He flow) prior to IM separation 
and provide the best separation (N2 flow, wave height, and wave velocity[15]). These 
parameters are protein dependent.   
6. When performing native IM-MS experiments, we slightly increase the concentration of 
the analyte compared to native MS experiments to compensate the loss of sensitivity due to 
the activation of the IM device.   
7. Record each IM experiment in triplicate to calculate a more reliable collision cross 
section. 
8. The c constant has been determined empirically and it is specific of the Synapt G2 mass 
spectrometer. For ion signals lower than 5000 m/z, c = 1.41. For ion signals above 5000 
m/z, c = 1.57[16].  
9. Other columns are available for SEC-native MS experiment. For a unique fast desalting 
goal, shorter column dimension (i.e. BEH SEC 4.6 x 30 mm, 200 Å, Waters) could be used. 
For a separation goal, longer column dimension (i.e. BEH SEC 4.6 x 150/300 mm, 200 Å, 
Waters) is preferred.  
10. The flow rate gradient provides improved sensitivity on the Synapt G2 HDMS mass 
spectrometer. 
11. The flow rate gradient method is a generic method which can be easily adapted. If the 
LC method is changed, do not forget to change events in MS file for directing salts to waste. 
12. SEC-native MS coupling provides higher MS spectral resolution and mass accuracy due 
to the more efficient desalting afforded by SEC compared to manual desalting. 
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6. Figure Captions 
 
 
Figure 1. Native MS analysis of deglycosylated brentuximab vedotin (Cysteine 
conjugate) on Exactive Plus EMR. a) Native mass spectrum corresponding to 
brentuximab vedotin. b) Deconvoluted mass spectrum representing the drug load 
distribution with the average DAR.  
 
Figure 2. NanoESI MS analysis in non-denaturing conditions of deglycosylated 
Inotuzumab Ozogamicin (IO), a lysine ADC, after direct infusion. a) Full scan 
native mass spectrum of IO representing the different DAR populations (from DAR 2 
to DAR 8). 
 
Figure 3. NanoESI IM-MS analysis in non-denaturing conditions of deglycosylated 
site-specific DAR4 ADC[8] after direct infusion. a) Native mass spectrum of 
deglycosylated site-specific DAR4 ADC. b) Arrival time distributions (ATDs) of 
different DAR 4 charge states observed in the mass spectrum. c) Experimental collision 
cross section (TWCCSN2) and drift times corresponding to the different charge state 
populations upon ion mobility separation.  
  
Figure 4. SEC-native MS analysis of deglycosylated inotuzumab ozogamicin 
(Lysine conjugate). a) SEC-UV chromatogram corresponding to ADC monomer. b) 
Deconvoluted mass spectrum representing the drug load distribution with the average 
DAR.  
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Figure 3. NanoESI IM-MS analysis in non-denaturing conditions of deglycosylated site-
specific DAR4 ADC8 after direct infusion. a) Native mass spectrum of deglycosylated 
site-specific DAR4 ADC. b) Arrival time distributions (ATDs) of different DAR 4 charge 
states observed in the mass spectrum. c) Experimental collision cross section (TWCCSN2) 
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Figure 4. SEC-native MS analysis of deglycosylated inotuzumab ozogamicin (Lysine 
conjugate). a) SEC-UV chromatogram corresponding to ADC monomer. b) Deconvoluted 
mass spectrum representing the drug load distribution with the average DAR. 
 
